首页 › 基金 › Fairmount Funds Management LLC › ZBIO
Fairmount Funds Management LLC 对 ZBIO 的持仓历史
ZENAS BIOPHARMA INC · 医疗保健
Fairmount Funds Management LLC 在 Q3 2026 的 13F 申报中披露持有 ZBIO(ZENAS BIOPHARMA INC)2,371,358 股,市值约 US$64.0M,约占其申报组合的 4.01%,在其申报持仓中市值排名第 9 位。 Fairmount Funds Management LLC 最近 9 个申报季度中有 9 个季度披露了 ZBIO 持仓,最早可追溯至 Q3 2024。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Fairmount Funds Management LLC 对 ZBIO 的持仓演变
Fairmount Funds Management LLC 于 Q3 2024 首次披露 ZBIO 持仓:1,892,806 股(约 US$32.0M)。 该持仓在 Q4 2025 达到峰值 2,209,025 股,市值约 US$80.2M。 在 9 次申报中,Fairmount Funds Management LLC 3 次增持、0 次减持、5 次保持不变。 最近一期申报(Q3 2026)显示持股 2,371,358 股、市值约 US$64.0M,环比增持 12,333 股。。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2024 | 1.89M | $32.03M | 新进 |
| Q4 2024 | 1.89M | $15.50M | 持有 |
| Q1 2025 | 1.89M | $14.95M | 持有 |
| Q2 2025 | 1.89M | $18.34M | 持有 |
| Q3 2025 | 1.89M | $42.02M | 持有 |
| Q4 2025 | 2.21M | $80.21M | 增持 |
| Q1 2026 | 2.36M | $46.12M | 增持 |
| Q2 2026 | 2.36M | $59.87M | 持有 |
| Q3 2026 | 2.37M | $63.96M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ZBIO 与 13F 数据
ZBIO(ZENAS BIOPHARMA INC)属于医疗保健行业。我们追踪的基金中还有 59 只申报持有 ZBIO,申报仓位最大的包括:SR ONE CAPITAL MANAGEMENT, LP (US$135.9M), NEA Management Company, LLC (US$108.5M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$85.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ZBIO 的基金
- SR ONE CAPITAL MANAGEMENT, LP 5.04M 股 · $135.87M · Q3 2026
- NEA Management Company, LLC 4.02M 股 · $108.51M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 67.20M 股 · $85.74M · Q3 2026
- Enavate Sciences GP, LLC 2.92M 股 · $78.73M · Q3 2026
- Royalty Pharma Sub-Manager, LLC 2.39M 股 · $64.41M · Q3 2026
- NVP Associates, LLC 1.84M 股 · $49.58M · Q3 2026
- Context Capital Management, LLC 31.05M 股 · $39.70M · Q3 2026
- Graham Capital Management, L.P. 21.25M 股 · $27.32M · Q3 2026
- EcoR1 Capital, LLC 789.50K 股 · $21.29M · Q3 2026
- ArrowMark Colorado Holdings LLC 527.98K 股 · $14.24M · Q3 2026
- Rock Springs Capital Management LP 502.08K 股 · $13.54M · Q3 2026
- NEXTBio Capital Management LP 426.74K 股 · $11.51M · Q3 2026
更多关于 Fairmount Funds Management LLC
常见问题
How long has Fairmount Funds Management LLC held ZBIO?
Fairmount Funds Management LLC has disclosed ZBIO holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Fairmount Funds Management LLC's current position in ZBIO?
As of Q3 2026, Fairmount Funds Management LLC holds 2.37M shares of ZBIO (ZENAS BIOPHARMA INC), valued at $63.96M, representing 4.01% of its reported portfolio and ranking #9.
Has Fairmount Funds Management LLC been buying or selling ZBIO?
In the latest 13F filing (Q3 2026), Fairmount Funds Management LLC increased its position in ZBIO. The position peaked in Q4 2025 at 2.21M shares.
Which other funds hold ZBIO?
Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 59 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.